CNY cancer practice plans to ramp up cutting-edge therapy after successful outpatient treatment

Gail Mauro (center) receives her final step-up dose of bispecific antibody therapy at Hematology-Oncology Associates of CNY. She is pictured here with her husband, Joe (right) along with HOA Physician Assistant and Clinical Manager Denise Lougee. Joe serves as Gail’s at-home caregiver, which is a requirement of this new program.

Courtesy of HOA

 

By 

Lung Cancer Information

Patient Newsletter 2024 July

Sarcoma Education Sheet

Melanoma, 20210031

The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.

Lung, IMM1104-101

A phase 1/2a open label study of IMM-1-104 in Participants with Un-resectable or Metastatic Previously Treated Pancreatic Cancer or RAS Mutated NSCLC or Melanoma

Lung, D798AC00001 “eVOLVE-Lung02”

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 < 50%.

Advance Directives for New York State

Patient Newsletter 2024 June

Cancer Q&A with HOA: Cancer Survivorship

June is cancer survivor’s month, and this morning we were joined by medical oncologist and hematologist Dr. Iqra Choudary from Hematology-Oncology Associates’ Auburn office.

Pages